Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Adipocytokine signaling pathway |
1件: JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
2 | AGE-RAGE signaling pathway in diabetic complications |
1件: JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
3 | Chemokine signaling pathway |
1件: JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
4 | Cholinergic synapse |
1件: JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
5 | EGFR tyrosine kinase inhibitor resistance |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
6 | Epstein-Barr virus infection |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
7 | Growth hormone synthesis, secretion and action |
1件: JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
8 | Hepatitis B |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
9 | Hepatitis C |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
10 | Herpes simplex virus 1 infection |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
11 | Human cytomegalovirus infection |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
12 | Human papillomavirus infection |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
13 | Human T-cell leukemia virus 1 infection |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
14 | Influenza A |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
15 | JAK-STAT signaling pathway |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
16 | Kaposi sarcoma-associated herpesvirus infection |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
17 | Leishmaniasis |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
18 | Measles |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
19 | Necroptosis |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
20 | NOD-like receptor signaling pathway |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
21 | Osteoclast differentiation |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
22 | Pancreatic cancer |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
23 | Pathways in cancer |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
24 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
25 | PI3K-Akt signaling pathway |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
26 | Prolactin signaling pathway |
1件: JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
27 | Signaling pathways regulating pluripotency of stem cells |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
28 | Th1 and Th2 cell differentiation |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
29 | Th17 cell differentiation |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
30 | Toxoplasmosis |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
31 | Tuberculosis |
2件: JAK1, JAK2 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |
32 | Viral carcinogenesis |
1件: JAK1 | D10308 | Baricitinib | 8件: 41, 46, 49, 50, 93, 107, 265, 325 |